119 related articles for article (PubMed ID: 27894167)
1. Salinomycin reduces stemness and induces apoptosis on human ovarian cancer stem cell.
Lee HG; Shin SJ; Chung HW; Kwon SH; Cha SD; Lee JE; Cho CH
J Gynecol Oncol; 2017 Mar; 28(2):e14. PubMed ID: 27894167
[TBL] [Abstract][Full Text] [Related]
2. Graphene Oxide-Silver Nanocomposite Enhances Cytotoxic and Apoptotic Potential of Salinomycin in Human Ovarian Cancer Stem Cells (OvCSCs): A Novel Approach for Cancer Therapy.
Choi YJ; Gurunathan S; Kim JH
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29494563
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Targeting of Ovarian Cancer Stem Cells Using Estrogen Receptor Beta Agonist.
He Y; Alejo S; Venkata PP; Johnson JD; Loeffel I; Pratap UP; Zou Y; Lai Z; Tekmal RR; Kost ER; Sareddy GR
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806169
[TBL] [Abstract][Full Text] [Related]
4. Astragaloside IV enhances the sensitivity of breast cancer stem cells to paclitaxel by inhibiting stemness.
Huang P; Li H; Ren L; Xie H; Chen L; Liang Y; Hu Y; Selistre-de-Araujo HS; Boussios S; Jhawar SR; Cui R; Zuo Q; Chen Q
Transl Cancer Res; 2023 Dec; 12(12):3703-3717. PubMed ID: 38193000
[TBL] [Abstract][Full Text] [Related]
5. Cancer stemness kinase inhibitor amcasertib: a promising therapeutic agent in ovarian cancer stem and cancer cell models with different genetic profiles.
Guler Kara H; Ozates NP; Asik A; Gunduz C
Med Oncol; 2023 Oct; 40(12):342. PubMed ID: 37891391
[TBL] [Abstract][Full Text] [Related]
6. Cancer stem cell drugs target K-ras signaling in a stemness context.
Najumudeen AK; Jaiswal A; Lectez B; Oetken-Lindholm C; Guzmán C; Siljamäki E; Posada IM; Lacey E; Aittokallio T; Abankwa D
Oncogene; 2016 Oct; 35(40):5248-5262. PubMed ID: 26973241
[TBL] [Abstract][Full Text] [Related]
7. A Novel ALDH1A1 Inhibitor Blocks Platinum-Induced Senescence and Stemness in Ovarian Cancer.
Muralikrishnan V; Fang F; Given TC; Podicheti R; Chtcherbinine M; Metcalfe TX; Sriramkumar S; O'Hagan HM; Hurley TD; Nephew KP
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884498
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of lysosomal TRPML1 channel eliminates breast cancer stem cells by triggering ferroptosis.
Fan C; Wu H; Du X; Li C; Zeng W; Qu L; Cang C
Cell Death Discov; 2024 May; 10(1):256. PubMed ID: 38802335
[TBL] [Abstract][Full Text] [Related]
9. Hysteroscopy in fertility-sparing management for early endometrial cancer: a double-edged sword.
Park JY
J Gynecol Oncol; 2017 Jan; 28(1):e16. PubMed ID: 27894168
[No Abstract] [Full Text] [Related]
10. Tetrandrine inhibits glioma stem-like cells by repressing β-catenin expression.
Zhang Y; Wen YL; Ma JW; Ye JC; Wang X; Huang JX; Meng CY; Xu XZ; Wang SX; Zhong XY
Int J Oncol; 2017 Jan; 50(1):101-110. PubMed ID: 27909720
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the efficacy of paclitaxel with curcumin combination in ovarian cancer cells.
Liu Z; Zhu YY; Li ZY; Ning SQ
Oncol Lett; 2016 Nov; 12(5):3944-3948. PubMed ID: 27895754
[TBL] [Abstract][Full Text] [Related]
12. Salinomycin Suppresses Tumorigenicity of Liver Cancer Stem Cells and Wnt/Beta-catenin Signaling.
Liu Q; Sun J; Luo Q; Ju Y; Song G
Curr Stem Cell Res Ther; 2021; 16(5):630-637. PubMed ID: 31971116
[TBL] [Abstract][Full Text] [Related]
13. The stem cell inhibitor salinomycin decreases colony formation potential and tumor-initiating population in docetaxel-sensitive and docetaxel-resistant prostate cancer cells.
Gruber M; Handle F; Culig Z
Prostate; 2020 Feb; 80(3):267-273. PubMed ID: 31834633
[TBL] [Abstract][Full Text] [Related]
14. Salinomycin effectively eliminates cancer stem-like cells and obviates hepatic metastasis in uveal melanoma.
Zhou J; Liu S; Wang Y; Dai W; Zou H; Wang S; Zhang J; Pan J
Mol Cancer; 2019 Nov; 18(1):159. PubMed ID: 31718679
[TBL] [Abstract][Full Text] [Related]
15. Three-Dimensional Tumor Models to Study Cancer Stemness-Mediated Drug Resistance.
Lamichhane A; Tavana H
Cell Mol Bioeng; 2024 Apr; 17(2):107-119. PubMed ID: 38737455
[TBL] [Abstract][Full Text] [Related]
16. Selected markers of ovarian cancer and their relation to targeted therapy (Review).
Markowska A; Kojs Z; Twardawa D; Pietras J; Markowska J
Exp Ther Med; 2024 May; 27(5):236. PubMed ID: 38628658
[TBL] [Abstract][Full Text] [Related]
17. Aggresome formation promotes ASK1/JNK signaling activation and stemness maintenance in ovarian cancer.
Chen Y; Qiang Y; Fan J; Zheng Q; Yan L; Fan G; Song X; Zhang N; Lv Q; Xiong J; Wang J; Cao J; Liu Y; Xiong J; Zhang W; Li F
Nat Commun; 2024 Feb; 15(1):1321. PubMed ID: 38351029
[TBL] [Abstract][Full Text] [Related]
18. The Role of Cancer Stem Cell Markers in Ovarian Cancer.
Frąszczak K; Barczyński B
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201468
[TBL] [Abstract][Full Text] [Related]
19. "DEPHENCE" system-a novel regimen of therapy that is urgently needed in the high-grade serous ovarian cancer-a focus on anti-cancer stem cell and anti-tumor microenvironment targeted therapies.
Wilczyński JR; Wilczyński M; Paradowska E
Front Oncol; 2023; 13():1201497. PubMed ID: 37448521
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
